Aurora Cannabis Delivers Impressive Financial Results for 2025
NASDAQ | TSX: ACB
Remarkable Financial Achievements
- Record Annual Global Medical Cannabis Net Revenue of $244.4 million, indicating a 39% year-over-year growth
- Achieved Record Adjusted EBITDA of $49.7 million, reflecting a staggering 261% increase year-over-year
- Generated Positive Free Cash Flow of $9.9 million
- Maintained a Strong Balance Sheet with approximately $185.3 million in Cash and a Debt-Free Cannabis Business
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) announces impressive financial and operational results for its fourth quarter and fiscal year ending March 31, 2025. This exceptional year reflects a strategic execution that has set the Company apart within a competitive landscape.
Executive Chairman and Chief Executive Officer Miguel Martin expressed, "We are pleased to report an exceptional year to our shareholders, underscored by record annual global medical net revenue, adjusted EBITDA, and positive free cash flow. These achievements underscore the thoughtful execution of our strategic plan and set us further apart from competitors, strengthening our foundation for sustained and profitable growth."
Fourth Quarter Highlights
(Unless stated otherwise, comparisons are drawn from fiscal Q4 2025, Q3 2025, and Q4 2024 results)
- Total net revenue reached $90.5 million, showing a 34% increase compared to $67.4 million from the previous year, primarily driven by 48% growth in global medical cannabis and 32% growth in plant propagation.
- Adjusted gross margin before fair value adjustments was 62% in Q4 2025, up from 50% in the prior year, with adjusted gross profit rising by 62% to $54.2 million.
- Medical cannabis accounted for $67.8 million in revenue, marking a 48% rise compared to the previous year.
- Aurora's consumer cannabis net revenue diminished to $8.2 million due to a strategic focus on prioritizing high-margin products.
Strategic Financial Insights
The financial stability and growth trajectory of Aurora Cannabis reflect its dedication to operational excellence. The rising revenues from international operations doubled, constituting a significant 61% of global medical cannabis revenue. Notably, plant propagation revenue soared 32%, affirming the benefits of expanded product offerings and optimizations.
For Q1 FY 2026, expectations indicate continued strong performance with a slight decline in revenue anticipated, primarily due to short-term declines in specific international markets. However, improvements are expected in subsequent quarters due to enhanced distribution and product innovations, with seasonal revenue gains in plant propagation too.
Outlook for the Upcoming Year
As Aurora looks ahead, expectations remain robust. The Company intends to sustain profitability while emphasizing innovation and global expansion. With positive adjusted EBITDA projected to persist and free cash flow anticipated to retain positivity, Aurora stands well-positioned for ongoing success.
Frequently Asked Questions
What financial milestones did Aurora Cannabis achieve in 2025?
Aurora achieved record annual global medical cannabis revenue of $244.4 million, representing 39% YoY growth, and a remarkable adjusted EBITDA of $49.7 million, a 261% increase YoY.
How did Aurora's performance in Q4 2025 compare to previous quarters?
In Q4 2025, Aurora reported net revenue of $90.5 million, a 34% increase from the prior year, with solid contributions from both medical cannabis and plant propagation.
What is expected for Aurora's fiscal Q1 2026?
Aurora expects continued strong cannabis revenue, with seasonal increases in plant propagation. However, a temporary decline is expected in revenue from some international markets.
What strategies underpin Aurora's recent success?
Aurora’s success stems from a commitment to operational excellence, strategic market expansion, and a focus on high-margin products in its medical cannabis operations.
How does Aurora Cannabis maintain its financial health?
Aurora has sustained a strong balance sheet with substantial cash reserves and no debt, which underlies its strategic investments for growth and innovation.
